RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

Source: 
Pharmaceutical Business Review
snippet: 

RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").